share_log

Transcode Therapeutics | DEFA14A: Others

Transcode Therapeutics | DEFA14A: Others

Transcode Therapeutics | DEFA14A：其他
美股SEC公告 ·  11/13 16:40

Moomoo AI 已提取核心訊息

Transcode Therapeutics, Inc. has issued an open letter to shareholders dated November 12, 2024, regarding a Special Meeting scheduled for November 22. The meeting's agenda includes a proposal for shareholders to authorize the Board of Directors to effect a reverse stock split if deemed necessary. The company's management and directors are seeking this authorization as a contingency plan to maintain their Nasdaq listing, which is contingent on the company's stock closing at $1.00 per share or more for any ten-day period before December 31, 2024. Failure to meet this requirement could result in Nasdaq delisting, which the company believes would materially affect its value and its ability to raise capital. The need to raise additional capital is urgent for the continuation of clinical trials and other operations. The management and directors of Transcode Therapeutics are unanimously in favor of maintaining the Nasdaq listing and are hopeful that the reverse split will not be necessary.
Transcode Therapeutics, Inc. has issued an open letter to shareholders dated November 12, 2024, regarding a Special Meeting scheduled for November 22. The meeting's agenda includes a proposal for shareholders to authorize the Board of Directors to effect a reverse stock split if deemed necessary. The company's management and directors are seeking this authorization as a contingency plan to maintain their Nasdaq listing, which is contingent on the company's stock closing at $1.00 per share or more for any ten-day period before December 31, 2024. Failure to meet this requirement could result in Nasdaq delisting, which the company believes would materially affect its value and its ability to raise capital. The need to raise additional capital is urgent for the continuation of clinical trials and other operations. The management and directors of Transcode Therapeutics are unanimously in favor of maintaining the Nasdaq listing and are hopeful that the reverse split will not be necessary.
Transcode Therapeutics, Inc. 於2024年11月12日向股東發佈了一封公開信，關於定於11月22日舉行的特別會議。會議議程包括提議股東授權董事會在認爲必要時實施反向股票拆分。公司的管理層和董事正在尋求這一授權，作爲維護其納斯達克上市的應急計劃，而這取決於公司股票在2024年12月31日前的任何十天期間收盤價達到1.00美元或以上。如未能滿足這一要求，可能導致納斯達克退市，公司認爲這將對其價值和融資能力產生重大影響。爲了繼續進行臨床試驗及其他運營，需要緊急增加資金。Transcode Therapeutics 的管理層和董事一致支持保持納斯達克上市，並希望不必進行反向拆分。
Transcode Therapeutics, Inc. 於2024年11月12日向股東發佈了一封公開信，關於定於11月22日舉行的特別會議。會議議程包括提議股東授權董事會在認爲必要時實施反向股票拆分。公司的管理層和董事正在尋求這一授權，作爲維護其納斯達克上市的應急計劃，而這取決於公司股票在2024年12月31日前的任何十天期間收盤價達到1.00美元或以上。如未能滿足這一要求，可能導致納斯達克退市，公司認爲這將對其價值和融資能力產生重大影響。爲了繼續進行臨床試驗及其他運營，需要緊急增加資金。Transcode Therapeutics 的管理層和董事一致支持保持納斯達克上市，並希望不必進行反向拆分。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間